Moderna ( ($MRNA) ) has released its Q4 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...
Bengaluru: Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a ...
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...
Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Super Micro Computer rises sharply, Nvidia sells its stake in SoundHound, Airbnb swings to a profit in the fourth quarter, and Moderna posts a wider-than-expected quarterly loss.
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...